PUMA Partners With adam&eveDDB to Bring New Global Brand Strategy to Life
5.12.2024 11:00:00 CET | Business Wire | Press release
New Brand Campaign in 2025 Will Be Focused on the Emotional Aspects of Sport
Global sports company PUMA, in partnership with creative agency adam&eveDDB, continues its journey of elevating the brand with a new brand marketing strategy in 2025, establishing PUMA as a leading sports performance brand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205156959/en/
Global sports company PUMA, in partnership with creative agency adam&eveDDB, continues its journey of elevating the brand with a new brand marketing strategy in 2025, establishing PUMA as a leading sports performance brand. (Photo: Business Wire)
Founded in 1948 by Rudolf Dassler, PUMA was born from a vision to craft footwear that empowers athletes to embody the agility, speed, and spirit of a puma itself. For 75 years, PUMA has been at the forefront of innovation, partnering with the world’s fastest athletes, iconic clubs, and legendary federations to push the boundaries of performance. Over the last few years sports culture has moved from a narrow focus on winning – sweat, grit and struggle against the odds – to a more authentic and human space.
With the recent appointment of Julie Legrand as Senior Director of Global Brand Strategy and Communications, PUMA aims to shape the next chapter of its unique journey. Legrand, who was previously the Global Brand Director of H&M and has over a decade of experience at Procter & Gamble, dedicated 2024 to refining PUMA’s brand DNA and architecture, crafting a distinct and bold position in the market. “Part of my mission when joining the PUMA team early this year, was to oversee and further elevate the PUMA brand in the minds of consumers. I am delighted to be working with adam&eveDDB to delve into our DNA and to develop a brand campaign for 2025 that brings to life our new global brand strategy. With their emotionally charged creativity we can build deeper, more meaningful connections with our consumer.”
For Richard Teyssier, PUMA Vice President Brand & Marketing, “PUMA is the home to some the best athletes, teams and ambassadors in the world and we have a clear ambition to position PUMA as a leading sport performance brand. We aim to be at the forefront of innovation and trends, not only on our products but especially when it comes to the brand and marketing. With adam&eveDDB, we found a partner capable of helping us build an emotional connection with our consumers, while unifying the PUMA brand under a single global strategy across our extensive sports portfolio. “
This year, PUMA partnered with adam&eveDDB, a creative company committed to placing emotion at the core of every interaction between businesses and consumers. adam&eveDDB’s strategy will elevate the brand by bringing PUMA’s impressive credentials to the fore, establishing it as the leading sports performance brand. “Communicating all that PUMA has to offer is a gift. Our teams in London and Berlin are immersed in all the feelings that get people moving; we can’t wait to tell the brand's unique story which has been so brilliantly distilled by Julie and the team,” said Miranda Hipwell, CEO at adam&eveDDB.
adam&eveDDB’s first global brand campaign for PUMA will launch in spring 2025. The PUMA account will be led by teams from adam&eveDDB’s London and Berlin offices.
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
adam&eveDDB |
adam&eveDDB is a creative agency based in London, Berlin, New York, and San Francisco. They believe in the power of creativity to unlock business advantages for brands. An agency that feels welcoming and responsible. We work with a range of clients including Amazon, CALM, PlayStation, Eurostar, Marmite, Lloyds Bank, Savills, Volkswagen and MARS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205156959/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom